Clinical Trials Browser

Breast Neoplasms, Neoplasm, Residual, Breast Neoplasms, Male

Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

Breast Neoplasms, Colonic Neoplasms, Melanoma, Rectal Neoplasms, Teratoma, Testicular Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Carcinoma, Ductal, Breast, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Clinical Trials

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

ETHAN - ET for Male BC

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer

PePPy

Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery

Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

Bicalutamide in Treating Patients With Metastatic Breast Cancer

Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1

Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab

Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer

Carboplatin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer

Capecitabine and Radiation Therapy in Treating Patients With Nonmetastatic Breast Cancer After Surgery

Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer

Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer

Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer

Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer

Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients

Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer

Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer

Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer

Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer

Docetaxel With or Without a Phytochemical in Treating Patients With Breast Cancer

Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer

Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer

Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer

Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases

Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy

Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer

Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer

Cryoablation Therapy in Treating Patients With Invasive Ductal Breast Cancer

Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer

Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer

Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer

Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Gemcitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer

Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer

Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer

Capecitabine, Vinorelbine, and Trastuzumab in Treating Patients With Metastatic Breast Cancer

Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer

Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer

Irinotecan and Cetuximab in Treating Patients With Metastatic Breast Cancer

Erlotinib and Gemcitabine in Treating Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline and/or a Taxane

Docetaxel, Capecitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer

Paclitaxel Poliglumex and Capecitabine in Treating Patients With Metastatic Breast Cancer

Vinflunine and Capecitabine in Treating Patients With Previously Treated Metastatic Breast Cancer

Docetaxel, Carboplatin, and Pegfilgrastim in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer

Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer

Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer